Taysha Gene Therapies to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11
May 04 2021 - 7:00AM
Business Wire
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a
patient-centric, clinical-stage gene therapy company focused on
developing and commercializing AAV-based gene therapies for the
treatment of monogenic diseases of the central nervous system (CNS)
in both rare and large patient populations, today announced that it
will report its financial results for the first quarter ended March
31, 2021, and host a corporate update conference call and webcast
on Tuesday, May 11, 2021, at 8:00 AM Eastern Time.
Conference Call Details Tuesday, May 11, at 8:00 AM
Eastern Time / 7:00 AM Central Time
Toll Free:
855-327-6837
International:
631-891-4304
Conference ID:
10014460
Webcast:
https://ir.tayshagtx.com/news-events/events-presentations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210504005337/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com Media Contact: Carolyn Hawley Canale
Communications carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Oct 2023 to Oct 2024